Birmingham, West Midlands -- (SBWIRE) -- 12/12/2013 -- Value Penny Stocks issues special report on Rambus Inc. (NASDAQ:RMBS), Krispy Kreme Doughnuts (NYSE:KKD), CYS Investments Inc (NYSE:CYS), Orexigen Therapeutics, Inc. (NASDAQ:OREX).
Rambus Inc. (NASDAQ:RMBS) opened its last trade at the price of $9.74. Its closing price was $10.00 after gaining 4.38% for the day. The company traded with the total volume of 3,499,568 shares, while its average trading volume remained 942,054.00 shares. The beta of this stock stands at 1.74. Rambus Inc. invents, develops, offers, and licenses technology solutions. The company also develops products and services in security, light-emitting diodes lighting and displays, and immersive mobile media.
For How Long RMBS will Fight for Profitability? Read This Trend Analysis report
Krispy Kreme Doughnuts (NYSE:KKD) percentage change plunged -4.75% to close at $18.05 with the total traded volume of 3,421,351 shares, along with average volume of 1.48 million shares. The 52 week range of the stock remained $8.96 - $26.63, while its day lowest price was $17.85. The share price hit the day highest price of $19.12. Krispy Kreme Doughnuts, Inc., together with its subsidiaries, operates as a branded retailer and wholesaler of doughnuts, beverages, and treats and packaged sweets worldwide. It owns and franchises Krispy Kreme stores.
Has KKD Found The Bottom And Ready To Gain Momentum? Find Out Here
CYS Investments Inc (NYSE:CYS) traded on volume of 3,365,028 shares in the last session against average volume of 2.93 million shares. The company started its trading session with the price of $7.79 and closed at $7.65 by scoring -1.92%. CYS Investments, Inc., a specialty finance company, invests in residential mortgage pass-through certificates in the United States. It also focuses on investing in residential mortgage-backed securities that are issued and the principal and interest of which are guaranteed by a federally chartered corporation (Agency RMBS).
Why Should Investors Buy CYS After the Recent Fall? Just Go Here and Find Out
Orexigen Therapeutics, Inc. (NASDAQ:OREX) started its last trading session with the price of $5.99 and closed at $5.56 by scoring -4.63%. The stock traded with total volume of 3,303,230 shares, while the average trading volume remained 2.63 million shares. The beta value of this stock stands at 2.14. Day range for the stock was $5.51 - $6.00. Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include Contrave, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic, which has completed Phase II clinical trials.
Will OREX Get Buyers Even After The Recent Rally? Find Out Here
About Value Penny Stocks:
Value Penny Stocks was made by Two Active traders, Steve and Wilson, whom have made a platform for traders in order to provide traders the #1 Penny Stock Newsletter which actually gives value to your money and makes your portfolio full of profits. We concentrate on small cap stocks that trade on NYSE, NASD, AMEX, OTCBB, and OTC exchanges. These are usually stocks that will trade under $5 a share and offer the utmost potential profit on your short or long term investment. We also devote ourselves to understanding the overall market situations and use this knowledge in order to gain a better perception during our stock picking decisions.
We at ValuePennyStocks.com are engaged in the business of marketing and advertising companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.
Please Read Our Full Disclaimer at: http://www.valuepennystocks.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)